Table 1.
Patients’ clinical and pathologic characteristics
| Characteristics | n = 292 | |
|---|---|---|
| Age at PET/CT, median (years) | 70 (IQR 65–74) | |
| Primary Gleason score at RP | ≤ 7 | 204 (69.9%) |
| ≥ 8 | 88 (30.1%) | |
| Pathologic primary tumour stage (pT) | ≤ pT2c | 140 (47.9%) |
| ≥ pT3a | 152 (52.1%) | |
| Pathologic regional lymph node stage (pN) | pN0 | 230 (78.8%) |
| pN1 | 62 (21.2%) | |
| Additional treatment after RP1 | 142 (48.6%) | |
| Radiation therapy | 107 (36.6%) | |
| ADT (within the last 6 months) | 35 (12.0%) | |
| PSA value prior to PET/CT, median (ng/ml) | 0.50 (IQR 0.35–0.70) | |
| 0.2–0.5 ng/ml (very low) | n = 151 | 0.35 (IQR 0.27–0.43) |
| > 0.5–1.0 ng/ml (low) | n = 141 | 0.71 (IQR 0.60–0.90) |
ADT androgen deprivation therapy, RP radical prostatectomy
1Multiple secondary treatments within a patient possible